Letters Prostate cancer screening

Evidence of overdiagnosis

BMJ 2011; 342 doi: https://doi.org/10.1136/bmj.d3700 (Published 14 June 2011) Cite this as: BMJ 2011;342:d3700
  1. Bernard Junod, researcher1,
  2. Robert M Kaplan, OBSSR director NIH2,
  3. Philippe Foucras, MD3,
  4. Dominique Dupagne, MD4,
  5. Philippe Nicot, MD5
  1. 1La Maison Neuve, F 35520, La Chapelle des Fougeretz, France
  2. 2UCLA, Los Angeles, CA, USA
  3. 358 ch Balanderie, Urzy France
  4. 42 r. Phalsbourg, Paris, France
  5. 575 av Leon Blum, Panazol, France
  1. junod.bernard{at}wanadoo.fr

Sandblom and colleagues’ paper compared the case fatality rate of prostate cancer between men randomly assigned to screening and those who were not invited for screening.1 A more reliable outcome of such a randomised controlled trial is the difference of mortality as a result of prostate cancer between intervention …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe